Similarly, different anti-TIM-3 mAbs combined with anti-PD-1 mAbs in the treatment of advanced lymphomas or NSCLC displayed higher efficacy than TIM-3 blockers alone (objective response rate (ORR): 42.9% vs. 0%; disease control rate (DCR): 42.9% vs. 11.1%) [167]. This evidence concerns the gene HAVCR2 and non-small cell lung carcinoma.